{"name":"Clayton Sleep Insititute","slug":"clayton-sleep-insititute","ticker":"","exchange":"","domain":"","description":"Clayton Sleep Institute is a specialized research organization focused on advancing sleep medicine through clinical trials and innovative treatments. The company is currently conducting Phase 3 trials for two key products: a Placebo Device & Nasacort combination and Thermosmart & placebo.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Placebo Device & Nasacort","genericName":"Placebo Device & Nasacort","slug":"placebo-device-nasacort","indication":"Seasonal allergic rhinitis","status":"phase_3"}]}],"pipeline":[{"name":"Placebo Device & Nasacort","genericName":"Placebo Device & Nasacort","slug":"placebo-device-nasacort","phase":"phase_3","mechanism":"Nasacort is a corticosteroid that works by reducing inflammation in the nasal passages.","indications":["Seasonal allergic rhinitis","Perennial allergic rhinitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQSHkya0lpUmZLbVV3X21ZdFVMMXNhb2hsNXY3RnAyczJ5VDFOX3ROeElSbzUwQjFhTTBPT1haQmZtTnFJc091VHVydWR6bUZjS21QMkNuNUl3VjlLV3MxZHRnMV81UzU4bEZhZmZNZlNaWDB3WFp4Und3Wks0Mi1lNVFwTGh6c3V2RTlMUk44Vm5TV2hxVUtIdzN3?oc=5","date":"2021-11-18","type":"pipeline","source":"Sleep Review","summary":"Joseph Ojile, MD, FCCP, DABSM - Sleep Review","headline":"Joseph Ojile, MD, FCCP, DABSM","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPaTdkMGhtOTRuRzhRdHpvTGRZNEdXTzY3VE1ybU5TUHdzZW41VWwzR2hlUTJYZ01iWUFlNHNHa19qZFNLR1dHSFV0dVlGaXBtUFFIX1QwTmR4TE5RQm5HMkVuMk5Lel9nSTYxWmljVXpBd0RwMEU2RmhDdDYtNEE4WFBqOE1Uc0xYU3ducFdKcEpBazRTeXp6WUQweDBDN3lSdGtxeW1kejFjZlF1?oc=5","date":"2014-05-23","type":"pipeline","source":"Sleep Review","summary":"Staying Ahead of the Curve - Sleep Review","headline":"Staying Ahead of the Curve","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}